Immune-mediated hemolytic anemia (IMHA) is an important disease in dogs that causes anemia (a low red blood cell count). We would like to be able to identify how a patient is responding to therapy using a blood test. We hope to identify how long it takes to see suppression of the immune markers in a blood sample during therapy and see if this varies by treatment regimen used. We will be looking at three different lymphocyte responses during treatment for IMHA. Our goal is to identify if one of these markers decreases more rapidly in response to immunosuppressive treatment, and if one treatment is best associated with patient survival at 1 month.
Dogs diagnosed with immune-mediated hemolytic anemia weighing more than 6 kg.
As part of the study, you will receive a free 2 and 4 week recheck with our Internal Medicine service. Cost of the blood draw will be covered by the study, as will the cost of the recheck red blood cell test (PCV).
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com
Is Your Pet Eligible?
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.
If you believe you have a patient who is eligible for this clinical trial study or you would like additional information from the Clinical Trials Office at the Cummings Veterinary Medical Center, complete a referring physician questionnaire.